Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment-Resistant Depression

Interventions

DRUG: MIJ821 Subcutaneous Injection 1 mg
DRUG: MIJ821 Subcutaneous Injection 4 mg
DRUG: MIJ821 Subcutaneous Injection 10 mg
DRUG: Placebo Subcutaneous Injection

Sponsor

Novartis Pharmaceuticals